U.S. Food and Drug Administration Approval: Neratinib for the Extended Adjuvant Treatment of Early-Stage HER2-Positive Breast Cancer-Reference-Cited by-同舟云学术

U.S. Food and Drug Administration Approval: Neratinib for the Extended Adjuvant Treatment of Early-Stage HER2-Positive Breast Cancer

Published:2018-03-09 Issue:15 Volume:24 Page:3486-3491
ISSN:1078-0432
Container-title:Clinical Cancer Research
language:en
Short-container-title:Clin Cancer Res

Author:

Singh Harpreet,Walker Amanda J.,Amiri-Kordestani Laleh,Cheng Joyce,Tang Shenghui,Balcazar Pamela,Barnett-Ringgold Kimberly,Palmby Todd R.,Cao Xianhua,Zheng Nan,Liu Qi,Yu Jingyu,Pierce William F.,Daniels Selena R.,Sridhara Rajeshwari,Ibrahim Amna,Kluetz Paul G.,Blumenthal Gideon M.,Beaver Julia A.,Pazdur Richard

Publisher

American Association for Cancer Research (AACR)

Subject

Cancer Research,Oncology

Cited by 76 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Neratinib plus dasatinib is highly synergistic in HER2-positive breast cancer in vitro and in vivo;Translational Oncology;2024-11

2. Patterns in use and tolerance of adjuvant neratinib in patients with hormone receptor (HR)-positive, HER2-positive early-stage breast cancer;Breast Cancer Research and Treatment;2024-08-17

3. Developing theragnostics for Alzheimer's disease: Insights from cancer treatment;International Journal of Biological Macromolecules;2024-06

4. Trastuzumab‐based nanomedicines for breast cancer therapy: Recent advances and future opportunities;Nano Select;2024-02-17

5. Molecular docking and molecular dynamics approach to identify EGFR and HER2 receptors inhibitory effect of compounds in Zanthoxylum simulans Hance;Vietnam Journal of Chemistry;2024-02